AU2005320905B2 - Pharmaceutical compositions for treating diseases associated with NF-kappaB activity - Google Patents

Pharmaceutical compositions for treating diseases associated with NF-kappaB activity Download PDF

Info

Publication number
AU2005320905B2
AU2005320905B2 AU2005320905A AU2005320905A AU2005320905B2 AU 2005320905 B2 AU2005320905 B2 AU 2005320905B2 AU 2005320905 A AU2005320905 A AU 2005320905A AU 2005320905 A AU2005320905 A AU 2005320905A AU 2005320905 B2 AU2005320905 B2 AU 2005320905B2
Authority
AU
Australia
Prior art keywords
nik
binding
agent
amino acids
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2005320905A
Other languages
English (en)
Other versions
AU2005320905A1 (en
Inventor
Parameswaran Ramakrishnan
Taisa Shmushkovich
David Wallach
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Yeda Research and Development Co Ltd
Original Assignee
Yeda Research and Development Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Research and Development Co Ltd filed Critical Yeda Research and Development Co Ltd
Publication of AU2005320905A1 publication Critical patent/AU2005320905A1/en
Application granted granted Critical
Publication of AU2005320905B2 publication Critical patent/AU2005320905B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1205—Phosphotransferases with an alcohol group as acceptor (2.7.1), e.g. protein kinases
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2005320905A 2004-12-27 2005-12-11 Pharmaceutical compositions for treating diseases associated with NF-kappaB activity Ceased AU2005320905B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IL166006 2004-12-27
IL16600604A IL166006A0 (en) 2004-12-27 2004-12-27 Pharmaceutical compositions for treating diseases associated with nf-kb activity
PCT/IL2005/001335 WO2006070348A1 (en) 2004-12-27 2005-12-11 PHARMACEUTICAL COMPOSITIONS FOR TREATING DISEASES ASSOCIATED WITH NF-κB ACTIVITY

Publications (2)

Publication Number Publication Date
AU2005320905A1 AU2005320905A1 (en) 2006-07-06
AU2005320905B2 true AU2005320905B2 (en) 2011-03-17

Family

ID=36072106

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2005320905A Ceased AU2005320905B2 (en) 2004-12-27 2005-12-11 Pharmaceutical compositions for treating diseases associated with NF-kappaB activity

Country Status (9)

Country Link
US (1) US8338567B2 (https=)
EP (1) EP1838347B1 (https=)
JP (1) JP5686940B2 (https=)
AU (1) AU2005320905B2 (https=)
CA (1) CA2593035C (https=)
ES (1) ES2518340T3 (https=)
IL (2) IL166006A0 (https=)
NO (1) NO20073942L (https=)
WO (1) WO2006070348A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2527434B1 (en) 2010-01-22 2017-08-09 Japan Science and Technology Agency Probe reagent for measurement of proteolytic activity
EP3041859A2 (en) * 2013-09-03 2016-07-13 INSERM - Institut National de la Santé et de la Recherche Médicale Compositions and methods for inducing senescence in cancer cells
US12059413B2 (en) 2016-11-02 2024-08-13 The Research Foundation For The State University Of New York Methods of inhibiting viruses using compositions targeting TSG101-ubiquitin interaction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854003A (en) * 1997-07-03 1998-12-29 Tularik Inc. Screening method for agents that modulate human NIK activity
WO2003087380A1 (en) * 2002-04-18 2003-10-23 Yeda Research And Development Co.Ltd Derivatives of the nf-kappab inducing enzyme, their preparation and use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4036945A (en) 1976-05-03 1977-07-19 The Massachusetts General Hospital Composition and method for determining the size and location of myocardial infarcts
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
AU2877899A (en) * 1998-02-27 1999-09-15 Regents Of The University Of California, The A novel inhibitor of the inflammatory response induced by tnfalpha and il-1
ITMI20010402U1 (it) 2001-07-18 2003-01-18 Valerio Leccacorvi Rivestimento per le superfici di una piscina

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5854003A (en) * 1997-07-03 1998-12-29 Tularik Inc. Screening method for agents that modulate human NIK activity
WO2003087380A1 (en) * 2002-04-18 2003-10-23 Yeda Research And Development Co.Ltd Derivatives of the nf-kappab inducing enzyme, their preparation and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Hu, Wen-Hui et al, J Biol Chem, 2000, Vol.275, No.15, pages 10838-10844 *

Also Published As

Publication number Publication date
US20090098106A1 (en) 2009-04-16
IL183926A (en) 2012-02-29
EP1838347A1 (en) 2007-10-03
NO20073942L (no) 2007-09-27
JP5686940B2 (ja) 2015-03-18
IL183926A0 (en) 2007-10-31
EP1838347B1 (en) 2014-10-01
IL166006A0 (en) 2006-01-15
ES2518340T3 (es) 2014-11-05
WO2006070348A1 (en) 2006-07-06
CA2593035C (en) 2014-10-14
US8338567B2 (en) 2012-12-25
AU2005320905A1 (en) 2006-07-06
JP2008525427A (ja) 2008-07-17
CA2593035A1 (en) 2006-07-06

Similar Documents

Publication Publication Date Title
US9181553B2 (en) Method of treatment of breast cancers over-expressing the SHP2 signature genes
Hannan et al. Affinity purification of mammalian RNA polymerase I: identification of an associated kinase
US20210277102A1 (en) Compositions and methods for treating a tumor suppressor deficient cancer
US20130259857A1 (en) Methods for inhibiting fascin
CA2660516A1 (en) Treating or preventing cancers over-expressing reg4 or kiaa0101
WO2008104979A2 (en) Nuclear targeting sequences
US20130028886A1 (en) Protein tyrosine phosphatase, non-receptor type 11 (ptpn11) and tumor initiating cells
Lecat et al. The c-Jun N-terminal kinase (JNK)-binding protein (JNKBP1) acts as a negative regulator of NOD2 protein signaling by inhibiting its oligomerization process
CA2547459C (en) Modulators of nik-siva complex formation for treating immune disorders
IL183926A (en) Agent capable of modulating nik-hc8 binding
US20100022626A1 (en) Modulators of cell migration and methods of identifying same
US20080305102A1 (en) Therapeutic Agent for Cancer Comprising Substance Capable of Inhibiting Expression or Function of Synoviolin as Active Ingredient and Screening Method for the Therapeutic Agent for Cancer
WO2005068618A1 (en) Polynucleotides encoding novel ubch10 polypeptides and kits and methods using same
WO2006093337A1 (ja) 癌の予防・治療剤
WO2005002413A2 (en) Methods and reagents for diagnosing gliomas and treating gliomas
WO2006114788A1 (en) Kinesin polypeptides, polynucleotides encoding same and compositions and methods of using same
KR20080056185A (ko) 신규한 치료 단백질 및 표적인 칼시뉴린의 보존된 막활성인자 (ｃｍａｃ)
US20090131349A1 (en) Methods and Compositions for Modulating Body Weight and for Treating Weight Disorders and Related Diseases
US20030225026A1 (en) Methods, compositions and articles of manufacture useful for treating mammary tumors
EP4063507A1 (en) Method for predicting sensitivity of cancer cells to helicase inhibitor
WO2005123127A2 (en) Methods for treating cancer using prss15 as a target
IL200578A (en) Nuclear targeting sequences
JP2001311734A (ja) 癌細胞の増殖能力を検査する方法

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired